Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial

医学 赛马鲁肽 体质指数 内科学 安慰剂 物理疗法 入射(几何) 累积发病率 心肌梗塞 心理干预 临床试验 疾病 随机对照试验 需要治疗的数量 置信区间 老年学 糖尿病 危险系数 人口 平衡(能力)
作者
John W. Ostrominski,Jorge Plutzky,Benjamin M. Scirica,G. Kees Hovingh,Ole Kleist Jeppesen,A. Michael Lincoff,Ildiko Lingvay,Thomas Hoffmann Morville,Maria Quiroga,Yael Sofer,Miguel A. Urina-Triana,Vanita R. Aroda,SELECT Trial Investigators,Djamel E. Nibouche,Mohamed Chettibi,Naima Hammoudi,Alejandro Porto,Alejandra Oviedo,Hugo Daniel Sanabria,Marcelo Casas
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:11 (11): 1103-1112 被引量:2
标识
DOI:10.1001/jamacardio.2026.3566
摘要

Importance: Whether frailty influences the benefit-risk balance of glucagon-like peptide-1 receptor agonists (GLP-1 RA) is uncertain. Objective: To evaluate whether frailty modifies the efficacy and safety of the GLP-1 RA semaglutide in adults with cardiovascular disease and overweight/obesity. Design, Setting, and Participants: In this secondary analysis of a randomized clinical trial, participants were adults with a body mass index of 27 or higher and established cardiovascular disease without diabetes. A 31-item frailty index (FI) was constructed using the Rockwood cumulative deficit approach; participants were categorized as not frail (FI ≤0.210), more frail (FI 0.211-0.310), and most frail (FI ≥0.311). Interventions: Semaglutide, 2.4 mg, once weekly or placebo. Main Outcomes and Measures: The primary composite outcome was cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Key secondary clinical outcomes, health-related quality-of-life (assessed by EuroQol 5-Dimension 5-Level [EQ-5D-5L] score), and safety events were additionally examined. Results: Of 17 604 participants, the mean (SD) age was 61.6 (8.9) years; 12 732 patients (72.3%) were male and 4872 were female (27.7%). A total of 5432 patients (31%) had an FI up to 0.210, 8349 (47%) had an FI of 0.211 to 0.310, and 3823 (22%) had an FI 0.311 or higher. The incidence of the primary outcome increased with higher baseline FI. Benefits of semaglutide vs placebo on the primary outcome appeared consistent across the FI categories (hazard ratio [HR], 0.84; 95% CI, 0.65-1.07, if the FI was ≤0.210; HR, 0.70; 95% CI, 0.59-0.82, if the FI was 0.211-0.310; HR, 0.92; 95% CI, 0.76-1.10, if the FI was ≥0.311; P = .09 for interaction). Similar findings were observed when the FI was examined continuously (P = .30 for interaction). Semaglutide additionally reduced the composite heart failure outcome (P = .82 for interaction), all-cause hospitalization (P = .71 for interaction), and all-cause mortality (P = .28 for interaction) regardless of FI category. Benefits of semaglutide on EQ-5D-5L scores appeared larger with higher FI (P = .02 for interaction). Between baseline and week 104, FI category was more likely to improve (odds ratio [OR], 2.46; 95% CI, 1.80-3.37), and less likely to worsen (OR, 0.47; 95% CI, 0.34-0.65) with semaglutide vs placebo. The HRs for adverse events leading to permanent discontinuation of semaglutide vs placebo appeared lower among participants with higher baseline FI (P < .001 for interaction). Conclusions and Relevance: This study found that semaglutide demonstrated beneficial effects on a broad range of clinical outcomes in SELECT, without detectable heterogeneity by baseline FI. Benefits of semaglutide on health-related quality of life appeared greater with higher FI. Trial Registration: ClinicalTrials.gov Identifier: NCT03574597.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被Trey采纳,获得10
1秒前
初景的应助被清脆慕山采纳,获得20
1秒前
WenjingziWang完成签到,获得积分10
1秒前
斯文败类的应助被着急的依波采纳,获得30
1秒前
2秒前
2秒前
青柠完成签到 ,获得积分10
3秒前
3秒前
斯文败类的应助被倾慕采纳,获得10
4秒前
molihuakai的应助被元旦采纳,获得10
5秒前
李垚发布了新的文献求助10
5秒前
瓢闻馅发布了新的文献求助10
6秒前
无极微光的应助被李半斤采纳,获得20
6秒前
ysgzg20123完成签到,获得积分10
6秒前
yao完成签到,获得积分10
7秒前
7秒前
7秒前
科研通AI2S的应助被咻咻咻采纳,获得10
7秒前
Maestro_S的应助被yh采纳,获得10
7秒前
安安完成签到 ,获得积分10
7秒前
科研通AI6.3的应助被yh采纳,获得10
8秒前
8秒前
pkfsp发布了新的文献求助10
9秒前
z66完成签到,获得积分10
9秒前
可爱的蓝天完成签到 ,获得积分10
9秒前
10秒前
10秒前
Noreason完成签到 ,获得积分10
10秒前
顾矜的应助被51515采纳,获得10
11秒前
11秒前
wenlin完成签到,获得积分10
12秒前
西大可怜虫完成签到,获得积分10
12秒前
13秒前
xixi发布了新的文献求助10
13秒前
wyp给张临秋的求助进行了留言
14秒前
香蕉觅云的应助被Bai采纳,获得10
14秒前
keggin发布了新的文献求助10
14秒前
15秒前
捡破烂的发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178695
求助须知:如何正确求助?哪些是违规求助? 9569449
关于积分的说明 21804643
捐赠科研通 7773744
什么是DOI,文献DOI怎么找? 3432903
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478500